{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000062","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.612134+00:00","generated_at":"2026-06-02T01:12:01.750667+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints","bullets":["Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.","End-of-Phase 2 meeting with FDA for episodic migraine resulted in preliminary alignment on Phase 3 design.","Completed $15M private placement with Daewoong; second installment received April 2024.","Seongsoo (Shawn) Park appointed to Board of Directors as Daewoong's representative.","Company evaluating next-steps across late-stage clinical pipeline for ABP-450."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000062","json":"https://secwatch.observer/filing/0001837607-24-000062.json","markdown":"https://secwatch.observer/filing/0001837607-24-000062.md","text":"https://secwatch.observer/filing/0001837607-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/0001837607-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/aeon-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:12:01.750667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7163f28618795cb951792c89a3e1503ce39e0ae6","claim":"AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/0001837607-24-000062-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}